NCT04693351 is a Phase 3 clinical trial of Troriluzole in Obsessive-Compulsive Disorder, sponsored by Biohaven Pharmaceuticals, Inc..

Who is sponsoring NCT04693351?

NCT04693351 is sponsored by Biohaven Pharmaceuticals, Inc..

What drugs are being tested in NCT04693351?

Interventions in NCT04693351: Troriluzole, Placebo.

What condition does NCT04693351 study?

NCT04693351 studies Obsessive-Compulsive Disorder.

Is NCT04693351 still recruiting?

NCT04693351 is currently completed. Last updated 19 August 2025.

Last reviewed 2025-08-19 · How we verify

NCT04693351

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety Study of Adjunctive Troriluzule in Obsessive Compulsive Disorder

Completed Phase 3 Last updated 19 August 2025

What this trial tests

Phase 3 trial testing Troriluzole in Obsessive-Compulsive Disorder in 589 participants. Completed in 29 April 2025.

Timeline

29 January 2021

Primary endpoint
29 April 2025

29 April 2025

Quick facts

Lead sponsor	Biohaven Pharmaceuticals, Inc.
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	589
Start date	29 January 2021
Primary completion	29 April 2025
Estimated completion	29 April 2025
Sites	89 locations across Italy, Netherlands, United Kingdom, Canada, China, United States, Spain

Drugs / interventions tested

Troriluzole — full drug profile →
Placebo

Conditions studied

Obsessive-Compulsive Disorder — all drugs for Obsessive-Compulsive Disorder →

Sponsor

Biohaven Pharmaceuticals, Inc. — full company profile →

Who can join

Adults 18 to 65, any sex, with Obsessive-Compulsive Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study's purpose its to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compulsive Disorder (OCD)

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Anxiety disorders, PTSD and OCD: systematic review of approved psychiatric medications (2008-2024) and pipeline phase III medications.
Tadros E, Keerthana S, Padder S, Totlani J, et al · · 2025 · cited 3× · PMID 40225810 · DOI 10.7573/dic.2024-11-2
CNS Summit 2021: Abstracts of Poster Presentations
· 2021 · cited 1×
CNS Summit 2022: Abstracts of Poster Presentations
· 2022

Verify or expand the search:

Other trials of Troriluzole

Trials testing the same drug.

NCT06552260 — A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma · EARLY_PHASE1 · recruiting
NCT04899921 — Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets · Phase 2 · terminated
NCT04641143 — Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder · Phase 3 · completed
NCT03829241 — Randomized Trial of Adult Participants With Generalized Anxiety Disorder · Phase 3 · completed
NCT03299166 — Troriluzole (BHV-4157) in Adult Participants With Obsessive Compulsive Disorder · Phase 2, PHASE3 · completed

Other recruiting trials for Obsessive-Compulsive Disorder

Currently open trials in the same condition.

NCT06575075 — Pilot Study of RR-HNK in OCD · Phase 1, PHASE2 · recruiting
NCT05783817 — MDMA-Assisted CBT for OCD (MDMA-CBT4OCD Study) · Phase 2 · recruiting
NCT07065669 — Treating Adolescent Obsessive Compulsive Disorder With Transcranial Magnetic Stimulation · NA · recruiting
NCT06376734 — Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness · Phase 2 · recruiting
NCT07000812 — EEG Evaluation of CBT for Obsessive-Compulsive Disorder · NA · active not recruiting

Other Biohaven Pharmaceuticals, Inc. trials

Trials by the same sponsor.

NCT04634435 — Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients · Phase 1 · completed
NCT04708834 — Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder · Phase 3 · terminated
NCT04641143 — Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder · Phase 3 · completed
NCT03952806 — Study of BHV-3241 in Participants With Multiple System Atrophy · Phase 3 · completed
NCT03829241 — Randomized Trial of Adult Participants With Generalized Anxiety Disorder · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04693351 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Biohaven Pharmaceuticals, Inc.
Last refreshed: 19 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04693351.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing